Champions Oncology, Inc. reported record annual revenue of $59.4 million for the fiscal year ended April 30, 2026, a 4% increase over the prior year. The company achieved positive Adjusted EBITDA in all four quarters of FY 2026, with annual Adjusted EBITDA of $1.6 million. Despite record revenue, the company reported a GAAP loss from operations of $1.1 million for the year, compared to income of $4.6 million in FY 2025, primarily due to the absence of non-recurring data license revenue and increased investments in radiopharmaceuticals and its commercial organization. The company ended the period with $4.9 million in cash and no debt. Champions Oncology is a global preclinical and clinical research services provider offering oncology R&D solutions and data platforms to biopharma organizations.